As of Jan 10, 2025, Apple Relative Value is $635.3. This suggests it may be overvalued by 8.8% compared to its current price of around $696.9.
As of Jan 10, 2025, Regeneron Pharmaceuticals, Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at $1,172.4. This suggests it may be overvalued by 68.2% to its current price of around $696.9, using a discount rate of 7.7% and terminal growth rate of 3.0%.
As of Jan 10, 2025, Apple Intrinsic Value is $890.7. This suggests it may be undervalued by 27.8% compared to its current price of around $696.9.